Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

First Blood-Based Lung Cancer EGFR Test Gets FDA Green Light

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche's cobas EGFR Mutation Test v2 liquid biopsy test is approved to detect genetic mutations linked to drug response in patients with non-small cell lung cancer treated with Tarceva.

Advertisement

Related Content

Roche Eyes Liquid Biopsy As A Boost To Drug Development, Cancer Monitoring
Diagnostics In 2015: Past Trends Coalesce, New Roads Open
New Products In Brief

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079524

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel